2025/01/24 17:53:39
Economic Daily Liu Meien
Summary
Based on a research paper by Dr. Chen Cheng-hsien, Professor of Internal Medicine at Taipei Medical University, the product has received positive feedback from consumers since its launch.
Translab’s Tangxinsheng FFL’s triple protection formula has been awarded the SNQ National Safety & Quality Award. Mr. Yang Zhonghan (left), founding secretary-general of the Taiwan Fucoidan Development Society (served from 2010 to 2020) and vice general manager of Translab International Ltd, presented to receive the SNQ National Quality award by Li Hongjun, vice president of the Control Yuan. (Photo provided by Translab International Ltd.)
After three years of development, Taiwanese health supplement Brand -Translab International Co., Ltd. has recently received the SNQ National Safety & Quality Mark certification for its new (FOII) 2nd generation small molecule fucoidan & Fucoxanthin (FUXII) product, “Translab’s Tangxinsheng FFL Triple Protection Formula.” This product, based on a research paper by Dr. Chen Cheng-hsien, a professor of internal medicine at Taipei Medical University, has passed IRB review for human clinical trials at the Taipei Medical Center, demonstrating the company’s strength in health food R&D and quality control.
Translab – Tangxinsheng (FFL) is an innovative product launched by Translab International Ltd., leveraging its second-generation small-molecule fucoidan technology. It contains three core ingredients: second-generation small-molecule fucoidan (FOII®), produced through high-pressure filtration and porous instant dissolution technology; second-generation highly stable fucoxanthin (FUXII®), produced through multiple precision processes; and L-carnitine.
Translab International stated that the company’s second-generation process technology, developed in 2020, achieved significant breakthroughs. The new technology utilizes a multi-step extraction process to more effectively remove excess impurities, preventing the interaction between functional ingredients and impurities that could affect their bioactivity. Furthermore, the new process significantly reduces the higher fat, monosaccharide, sucrose, and protein content of the first-generation technology, making the product more suitable for health and wellness purposes.
Mr. Yang Zhonghan, founder Secretary-General of the Taiwan Fucoidan Development Society (served from 2010 to 2020) and Deputy General Manager of Translab International Ltd., noted that in the fiercely competitive health supplements market, the company consistently adheres to a scientific and evidence-based approach, ensuring product quality through rigorous R&D processes and high-standard testing standards. “From raw material selection to process control, every step is rigorously scrutinized,” Yang emphasized.
The company utilizes a professional PIC/S GMP pharmaceutical facility for production, with raw materials batch-by-batch testing to ensure contamination-free. The production process adheres to the highest standards, including the rigorous selection of pure, natural sources, professional process controls, and multiple international standard testing, providing consumers with complete safety assurance. Mr. Yang Zhonghan stated that with the advent of a super-aging society, the company is committed to providing consumers with cost-effective healthcare options.
It’s particularly noteworthy that Translab Tangxinsheng (FFL) achieved both SNQ national safety & quality certification and IRB approval for human clinical trials at a teaching hospital within less than a year of its launch. This achievement not only demonstrates Translab International’s R&D strength in the health supplements sector but also reflects the company’s commitment to product safety and quality. The product has already begun its first phase of a one-year human clinical trial, and ongoing follow-up will be conducted to verify its effectiveness.
Mr. Yang Zhonghan further stated, “In the health supplements market, the most important things are product safety and actual effectiveness. We use rigorous scientific research and high-standard testing standards to ensure that users can feel the actual effects under the premise of safety.” As the trend of aging population becomes increasingly obvious, Translab International hopes to provide consumers with better health care options with innovative technology and strict quality control.
For more information, please refer to:：https://www.translablife.com
Dr. Chen Zhengxian is confident in the quality of Translab’s products.
Dr. Chen Zhengxian, professor of internal medicine at Taipei Medical University (Taiwan), highly praised the quality of Translab International’s new product, “Tangxinsheng (FFL).” He stated that obtaining the SNQ national quality award certification signifies that the product meets stringent standards in all aspects, including production processes and raw material inspection. “This is a certification that is very difficult to obtain.”
Professor Dr. Chen Zhengxian of the Department of Internal Medicine, at Taipei Medical University (Taiwan)
The product has already passed the standard clinical trial review process, and research is ongoing. Dr. Chen Zhengxian shared that several users have provided positive feedback during clinical observation, and further clinical research will be conducted to verify the results.
Dr. Chen Zhengxian stated that he personally uses this product. “Although, as a healthy person, I haven’t experienced any particular effects, I have full confidence in this formula because it’s based on solid scientific research,” he emphasized.
Furthermore, the latest generation of manufacturing process technology has also brought significant breakthroughs in the research and application of fucoxanthin. Dr. Chen Zhengxian explained that the biggest problem with fucoxanthin was its instability.
“Typically, fucoxanthin has a half-life of only tens of minutes, and it easily binds to oxidizing factors in the environment, losing its activity.” By leveraging patented technology licensed from National Taiwan Ocean University, Translab International has successfully extended the stability of fucoxanthin by developing a special stabilizing factor. This technological breakthrough not only ensures product efficacy but also opens up new possibilities for future research.
Dr. Chen Zhengxian particularly commended Translab International for its willingness to invest in human clinical trials and its achievement of the SNQ national safety & quality award. He stated that this demonstrates the company’s commitment to product safety and quality, “allowing us to truly translate our years of research findings into practical applications.” He also expressed optimism about Translab International’s future research and development in fucoidan, and expressed hope that they will continue to contribute to the health of the Taiwanese people through in-depth research.
